Please wait while the transcript is being prepared...
0:00
Hello, everyone, I'm
Professor Jarrko Rautio
from the School of Pharmacy
University of Eastern Finland.
The subject of my talk is prodrugs
and their role in drug delivery.
In general, prodrugs can provide
a means of solving drug delivery
challenges associated
with many new chemical
entities having larger and more
complex molecular structures.
In fact, prodrugs are
becoming an integral part
of the drug discovery
paradigm in some
large pharmaceutical companies.
Also, a number of
small biotech companies
have built around to design
an application of prodrugs
to improve their drug candidates.
I myself have a 15-year
experience with prodrugs,
and I have been working on several
various product applications
so far.
For example, in the early
stages of my research carrier,
I studied dermal prodrugs.
This was followed by research
on water soluble prodrugs
mostly on phosphates and then on
cytochrome p450 activated prodrugs,
which were targeted to the liver.
My most recent studies have focused
on sulphenamide prodrug approach
to increase the lipophilicity of a
very hydrophilic and basic quantity
in drug.
And we have also spent
quite a lot of time
with prodrugs which are designed
to take advantage of amino acid
transporters at the
blood-brain barrier
and to be taken up into the brain.
1:19
I have divided my
presentation into four parts.
First, I'm going to
tell what prodrugs are.
Then in the second part,
I'll show in one slide
the most common functional groups
and drugs amenable to prodrug
design as well as the most
common prodrug structures
for this functional groups.
Then the main part
of my presentation
will be dedicated to
prodrug examples that
have been approved for marketing.
These examples are
roughly divided based
on various problems or
barriers which have been
overcome in prodrug approaches.
Finally, at the end of my talk,
I'll show some prodrug statistics,
and I'm sure that the numbers
I'll show will surprise some.
